Vecima Introduces Industry's First Compact Generic Access Platform (GAP) Node Designed for 4 GHz
Vecima Networks Inc. (VCM: TSX) today announced the launch of its Entra EN3400 Compact Generic Access Platform (GAP) Node, deployed as either a two-port, Remote PHY (R-PHY)-enabled cable access node supporting DOCSIS 4.0 or a two-port All-PON™ node.
In October 2021, Vecima announced the Entra EN9000, the world's first commercially available GAP node, which is now in broad deployment with a Tier 1 Broadband Service Provider in North America. The EN3400 Compact GAP Node is a future-proof, 'Forever Node' with a 4.0 GHz-capable housing supporting the same DOCSIS 3.1 Remote PHY and 10G-EPON modules as the EN9000 today, while seamlessly evolving to XGS-PON, DOCSIS 4.0, NRoC (New Radio over Coax) and future HFC and PON solutions.
Building on the interoperability of the EN9000, its open architecture allows operators to select the best solutions from a variety of vendors, driving down costs and ensuring network agility and scalability. Through future module upgrades for Unified DOCSIS 4.0, the EN3400 is targeting delivery of up to 20 Gbps downstream and 6 Gbps upstream as a Distributed Access Architecture (DAA) cable access node.
In addition, the EN3400 offers flexible power options, including both standard AC power and 60/90V cable powering to support multi-dwelling unit, enterprise, and hospitality applications. This flexibility translates into significant long-term savings and operational efficiency by reducing the need for frequent hardware upgrades or replacements.
'The Entra EN3400 is the latest product from Vecima, building on the success of the original EN9000 GAP Node,' said Ryan Nicometo, Senior Vice President and General Manager, Video & Broadband Solutions. 'Designed for 4 GHz, the EN3400 is a high-performance, multi-application solution with a unique form factor suitable for MDU, hospitality, and enterprise deployments long into the future.'
Learn more about the Entra EN3400 at vecima.com/broadband-access/en3400.
This news release contains forward-looking statements within the meaning of applicable Canadian securities laws. Forward-looking statements include, but are not limited to, statements regarding Vecima's business strategies and objectives, and the anticipated benefits, performance, capabilities, availability or adoption of its products and services. Such statements reflect current expectations and assumptions about future events and are subject to risks and uncertainties. Vecima undertakes no obligation to update any forward-looking statements unless required by law.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250602885101/en/
CONTACT: Vecima Networks, Inc.
Media Relations:[email protected]
Investor Relations: 250-881-1982,[email protected]
KEYWORD: NORTH AMERICA CANADA
INDUSTRY KEYWORD: TECHNOLOGY AUDIO/VIDEO TELECOMMUNICATIONS MOBILE/WIRELESS SOFTWARE NETWORKS INTERNET
SOURCE: Vecima Networks Inc.
Copyright Business Wire 2025.
PUB: 06/02/2025 07:30 AM/DISC: 06/02/2025 07:28 AM
http://www.businesswire.com/news/home/20250602885101/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Gwich'in Tribal Council appoints new interim CEO
The Gwich'in Tribal Council has appointed a new interim chief executive officer to help advise the grand chief and oversee the organization's programs. Brenda McDonald replaces Mark Ellwood as CEO. In a statement Sunday, the Gwich'in Tribal Council announced her appointment, writing that McDonald brings more than two decades of experience working in senior leadership with Indigenous governments, and territorial and federal agencies. The statement says McDonald has managed multi-million dollar budgets, led diverse teams and delivered programs that strengthen local economies and support community priorities. Previous CEO, Ellwood, took over after the board moved to dismiss Jamie Koe earlier this year. McDonald began working as CEO immediately.
Yahoo
15 minutes ago
- Yahoo
Ditch the dust for good — this 'powerful and convenient' electric duster is 60% off on Amazon
It's lightweight, rechargeable and crazy strong. If you feel like you're constantly battling dust — whether it's sneaking onto your keyboard, clinging to your shelves or hiding in the nooks and crannies of your vehicle — then this Compressed Electric Air Duster could change the way you clean. This small but mighty gadget blasts away debris in seconds, helping keep your space spotless without the waste or cost of canned air. The compact yet powerful tool uses strong blasts of air to sweep away dust and crumbs and for a limited time, it's 60 per cent off on Amazon Canada. The details Lightweight and cordless, this compressed electric air duster is perfect for cleaning delicate electronics like laptops, consoles and cameras without the moisture or chemicals found in canned air. Beyond its practical functionality, it's surprisingly fun and satisfying to use. Powered by a robust 100,000 RPM motor, it delivers a strong, focused stream of air that targets hard-to-reach spots. Thanks to its rechargeable battery, you can easily take it from room to room, enjoying multiple cleaning sessions on a single charge. Plus, with USB-C fast charging, you'll be back up and running in no time. The duster also comes with a full set of attachments, including various nozzle types for precise cleaning and a brush head for loosening tough debris. The versatile nozzles make it simple to tackle everything from wide surfaces to tiny crevices, giving you full control over your cleaning. And if that's not enough, there's an eco-friendly bonus: unlike disposable canned air, this rechargeable duster produces no chemical waste or propellants. It's a cleaner, greener way to keep your space dust-free. What reviewers are saying 💨 650+ reviews ⭐ 4.1/5 stars 🏅 "The best alternative to compressed air!" This gadget is proving to be rather popular among Amazon shoppers. One happy customer raved, "It's lightweight, powerful and super convenient to use — the best alternative to compressed air!" Another adds, "The power it delivers is impressive." While most are thrilled with their purchase, one reviewer noted that there is no low-battery warning on the device, however they added that the battery life holds up well for typical use. Another reviewer mentioned that, "while it's a bit loud, the performance more than makes up for the noise." It's definitely clear that shoppers are impressed by this gadget, and with savings this steep, now may be the time to give it a try. 5 more really good Amazon deals
Yahoo
15 minutes ago
- Yahoo
Xenon Reports Second Quarter 2025 Financial Results & Business Update
– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026– Phase 3 azetukalner neuropsychiatric studies underway with X-NOVA3 in MDD and X-CEED in BPD recently initiated– Phase 1 healthy volunteer study initiated for lead Nav1.7 development candidate for pain– Darren Cline appointed as Chief Commercial Officer to lead commercial build and anticipated azetukalner launch– Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. 'The completion of patient recruitment for our Phase 3 X-TOLE2 study is a significant milestone in the development of azetukalner and keeps us on track to report topline results in early 2026 in anticipation of our first potential approval and commercial product as a company. We remain highly encouraged by the potential value proposition of azetukalner as a novel, next-generation treatment option for people living with the debilitating effects of uncontrolled seizures,' said Ian Mortimer, President and Chief Executive Officer of Xenon. 'In addition, we remain excited about azetukalner's potential beyond epilepsy, with Phase 3 programs underway across multiple neuropsychiatric indications, with the initiation of our Phase 3 X-CEED study in bipolar depression, alongside two clinical studies now underway in our ongoing Phase 3 X-NOVA program in major depressive disorder.' 'We also continue to make significant progress within our early-stage portfolio, advancing multiple drug candidates targeting promising sodium and potassium channel targets, and we are currently conducting two first-in-human studies within our Kv7 and Nav1.7 programs. As we enter this catalyst-rich period, we remain focused on advancing and delivering innovative therapeutics to patients living with epilepsy, depression, and pain.' continued Mr. Mortimer. Business Highlights and Anticipated Milestones Azetukalner Clinical Development Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD) and bipolar depression (BPD). Epilepsy Programs Phase 3 X-TOLE2 clinical study of azetukalner in FOS has now completed patient recruitment, with topline data anticipated in early 2026. Phase 3 X-TOLE3 clinical study of azetukalner in FOS continues to enroll patients and is intended to support potential regulatory submissions in ex-U.S. jurisdictions. Phase 3 X-ACKT clinical study of azetukalner in PGTCS continues to enroll patients and is intended to support regulatory submissions for an additional epilepsy indication. The Company had four abstracts accepted to present at the 36th International Epilepsy Congress (IEC) taking place August 30 to September 3, 2025 in Lisbon, Portugal. Neuropsychiatric Programs X-NOVA2 and X-NOVA3, the first two of three planned Phase 3 clinical trials evaluating azetukalner in patients with MDD, are now underway and screening patients. X-CEED, the first of two planned Phase 3 clinical studies evaluating azetukalner in patients with BPD I and BPD II depression, has been initiated. Early-Stage Pipeline: Next-Generation Ion Channel Modulators Xenon continues to expand its portfolio by leveraging its extensive expertise to discover and develop potassium and sodium channel therapeutics, with the goal of filing multiple INDs, or equivalent, in 2025. Phase 1 study in healthy adult participants is underway for XEN1120, a Kv7 channel opener in development for pain. Work remains ongoing with additional Kv7 development molecules and chemistries with the hypothesis that Kv7 may have utility in a broad range of therapeutic indications including seizure disorders, pain, and neuropsychiatric disorders, such as MDD and BPD. Phase 1 study was initiated for XEN1701, the Company's lead Nav1.7 development candidate for pain. IND-enabling work remains ongoing for additional Nav1.7 candidates. Nav1.7 is an important pain-related target, based on strong human genetic validation, which may represent a new class of medicines without the limitations of opioids. Nav1.1 lead candidate is expected to enter IND-enabling studies in 2025, with pre-clinical data suggesting that targeting Nav1.1 could potentially address the underlying cause and symptoms of Dravet Syndrome. Xenon plans to host multiple R&D webinars with focus on early-stage pipeline programs. The first webinar will take place on October 2, 2025, and focus on our approach to treating pain with drug candidates targeting Nav1.7 and Kv7. Partnered Program As part of Xenon's ongoing collaboration with Neurocrine Biosciences, a Phase 1 study is underway for NBI-921355, an investigational, selective inhibitor of voltage-gated sodium channels Nav1.2 and Nav1.6 in development for the potential treatment of certain types of epilepsy. Corporate The Company appointed Darren Cline to Chief Commercial Officer (CCO). Cline brings extensive commercial expertise to lead the transition of Xenon to a commercial-stage company with the anticipated launch of azetukalner across three potential indications. Second Quarter Financial Results Cash and cash equivalents and marketable securities were $624.8 million as of June 30, 2025, compared to $754.4 million as of December 31, 2024. Based on current operating plans, including the completion of the azetukalner Phase 3 epilepsy studies and supporting late-stage clinical development of azetukalner in MDD and BPD, Xenon anticipates having sufficient cash to fund operations into 2027. As of June 30, 2025, there were 76,939,811 common shares and 2,173,081 pre-funded warrants outstanding. Research and development expenses for the quarter ended June 30, 2025 were $75.0 million, compared to $49.7 million for the same period in 2024. The increase of $25.3 million was primarily attributable to the ongoing azetukalner Phase 3 clinical trials in epilepsy and MDD, as well as start-up costs for the azetukalner Phase 3 BPD clinical trial, and increased personnel-related costs due to an increase in employee headcount. General and administrative expenses for the quarter ended June 30, 2025 were $19.2 million, compared to $19.4 million for the same period in 2024. Other income for the quarter ended June 30, 2025 was $8.9 million, compared to $10.8 million for the same period in 2024. The decrease of $2.0 million was primarily attributable to lower interest income, partially offset by an increase in foreign exchange gain. Net loss for the quarter ended June 30, 2025 was $84.7 million, compared to $57.9 million for the same period in 2024. The increase in net loss was primarily attributable to higher research and development expenses driven by the azetukalner program, increased personnel-related costs, and lower interest income. Conference Call Information Xenon will host a conference call and webcast today at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss its second quarter 2025 results. A listen-only webcast can be accessed on the Investors section of the Xenon website, with a replay available following the event. Participants can access the conference call by dialing (800) 715-9871 or (646) 307-1963 for international callers and referencing conference ID 4102397. About Azetukalner Phase 3 Epilepsy Program Xenon's Phase 3 epilepsy program includes three Phase 3 clinical trials in focal onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS). Designed closely after the Phase 2b X-TOLE clinical trial, the Phase 3 X-TOLE clinical trials are multicenter, randomized, double-blind, placebo-controlled studies evaluating the clinical efficacy, safety, and tolerability of 15 mg or 25 mg of azetukalner administered orally with food as adjunctive treatment in approximately 360 patients with FOS per study. The primary efficacy endpoint is the median percent change (MPC) in monthly seizure frequency from baseline through the 12-week double-blind period (DBP) of azetukalner compared to placebo. X-ACKT is a multicenter, randomized, double-blind, placebo-controlled study evaluating the clinical efficacy, safety, and tolerability of 25 mg of azetukalner administered with food as adjunctive treatment in approximately 160 patients with PGTCS. The primary efficacy endpoint is the MPC in monthly PGTCS frequency from baseline through the 12-week DBP of azetukalner compared to placebo. Upon completion of the DBP in the Phase 3 epilepsy studies, eligible patients may enter an OLE study for up to three years. About Azetukalner Phase 3 MDD X-NOVA Program Xenon's Phase 3 MDD program includes three multicenter, randomized, double-blind, placebo-controlled clinical trials to evaluate the clinical efficacy, safety, and tolerability of 20 mg of azetukalner administered orally with food over the 6-week double-blind period (DBP) as monotherapy treatment in approximately 450 patients with moderate-to-severe major depressive disorder (MDD) per study. The primary efficacy endpoint is the change from baseline in the HAM-D17 score at week 6 in patients who received azetukalner compared to placebo. Upon completion of the DBP, eligible patients may enter an open-label extension (OLE) study for up to 12 months. About Azetukalner Phase 3 BPD X-CEED Program Xenon's Phase 3 BPD program includes two multicenter, randomized, double-blind, placebo-controlled clinical trials to evaluate the clinical efficacy, safety, and tolerability of 20 mg of azetukalner administered orally with food over the 6-week double-blind period (DBP) as monotherapy treatment in approximately 400 patients per study with bipolar depression (BPD) I or II. The primary efficacy endpoint is the change from baseline in the MADRS score at week 6 in patients who received azetukalner compared to placebo. Upon completion of the DBP, eligible patients may enter an OLE study for up to 12 months. About Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon's lead molecule, azetukalner, is a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including Kv7 and Nav1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit and follow us on LinkedIn and X. Safe Harbor Statement This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 and Canadian securities laws. These forward-looking statements are not based on historical fact, and include statements regarding the timing of and potential results from clinical trials; the potential efficacy, safety profile, future development plans in current and anticipated indications, addressable market, regulatory success and commercial potential of our and our partners' product candidates; the efficacy of our clinical trial designs; our ability to successfully develop and achieve milestones in our azetukalner and other pipeline and development programs, including the anticipated filing of INDs and NDAs; the timing and results of our interactions with regulators; our ability to successfully develop and obtain regulatory approval of azetukalner and our other product candidates; and anticipated timing of topline data readout from our clinical trials of azetukalner. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events, or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: clinical trials may not demonstrate safety and efficacy of any of our or our collaborators' product candidates; promising results from pre-clinical development activities or early clinical trial results may not be replicated in later clinical trials; our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations may be incorrect; our ongoing discovery and pre-clinical efforts may not yield additional product candidates; any of our or our collaborators' product candidates, including azetukalner, may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; we may not achieve additional milestones in our proprietary or partnered programs; regulatory agencies may impose additional requirements or delay the initiation or completion of clinical trials; the impact of market, industry, and regulatory conditions on clinical trial enrollment; the impact of competition; the impact of expanded product development and clinical activities on operating expenses; the impact of new or changing laws and regulations; the impact of unstable economic conditions in the general domestic and global economic markets; adverse conditions from geopolitical events; as well as the other risks identified in our filings with the U.S. Securities and Exchange Commission and the securities commissions in British Columbia, Alberta, and Ontario. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. 'Xenon' and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner. Contacts: For Investors:Chad Fugere Vice President, Investor Relations(857) 675-7275investors@ For Media:Colleen AlabisoSenior Vice President, Corporate Affairs(617) 671-9238media@ XENON PHARMACEUTICALS Consolidated Balance Sheets(Expressed in thousands of U.S. dollars) June 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents and marketable securities $ 487,545 $ 626,905 Other current assets 12,707 8,359 Marketable securities, long-term 137,297 127,496 Other long-term assets 36,732 35,379 Total assets $ 674,281 $ 798,139 Liabilities Current liabilities: Accounts payable and accrued liabilities $ 31,588 $ 34,221 Other current liabilities 1,459 1,369 Other long-term liabilities 7,256 7,646 Total liabilities $ 40,303 $ 43,236 Shareholders' equity $ 633,978 $ 754,903 Total liabilities and shareholders' equity $ 674,281 $ 798,139XENON PHARMACEUTICALS Consolidated Statements of Operations and Comprehensive Loss(Expressed in thousands of U.S. dollars except share and per share amounts) Three Months EndedJune 30, Six Months EndedJune 30, 2025 2024 2025 2024 Revenue $ — $ — $ 7,500 $ — Operating expenses: Research and development 74,985 49,702 136,185 93,952 General and administrative 19,244 19,402 38,282 34,193 Total operating expenses 94,229 69,104 174,467 128,145 Loss from operations (94,229 ) (69,104 ) (166,967 ) (128,145 ) Other income 8,897 10,847 17,015 22,369 Loss before income taxes (85,332 ) (58,257 ) (149,952 ) (105,776 ) Income tax recovery (expense) 626 333 199 (79 ) Net loss $ (84,706 ) $ (57,924 ) $ (149,753 ) $ (105,855 ) Other comprehensive income (loss): Unrealized gain (loss) on available-for-sale securities 949 (443 ) 1,725 (2,135 ) Comprehensive loss $ (83,757 ) $ (58,367 ) $ (148,028 ) $ (107,990 ) Net loss per common share: Basic and diluted $ 1.07 $ (0.75 ) $ 1.90 $ (1.36 ) Weighted average common shares outstanding: Basic and diluted 78,953,445 77,671,128 78,820,474 77,632,864 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
